1. Complex: PD-L1 in complex with avelumab
Resolution: 3.2 Å
Species: H. sapiens
2. Antigen: Programmed death-ligand 1, PD-L1, cluster of differentiation 274, CD274, B7 homolog 1, B7-H1
structure length (residues): 221
mutations: No
3. Antibody: avelumab
Isotype/subclass: IgG1
Structure: Fab only
3.1 Heavy chain
structure length (residues): 120
mutations: No
disulfide bridges: 22-96
CDR (residue numbering): 27, 28, 31, 33, 52, 54, 55, 57, 59, 101, 102-106
3.2 Light chain
structure length (residues): 110
mutations: No
disulfide bridges: 22-90
CDR (residue numbering): 32, 34, 93, 95, 97, 99
RCSB PDB - 5GRJ: Crystal structure of human PD-L1 in complex with monoclonal antibody avelumab
PD-L1 in complex with antibody avelumab (310K, 37°C, 100 ns)
PD-L1 in complex with antibody avelumab (311K, 38°C, 100 ns)
PD-L1 in complex with antibody avelumab (312K, 39°C, 100 ns)
PD-L1 in complex with antibody avelumab (313K, 40°C, 100 ns)
1. Complex: PD-L1 in complex with Fab of BMS-936559 mAb
Resolution: 2.8 Å
Species: H. sapiens
2. Antigen: Programmed death-ligand 1, PD-L1, cluster of differentiation 274, CD274, B7 homolog 1, B7-H1
structure length (residues): 117
mutations: No
3. Antibody: BMS-936559 mAb
Isotype/subclass: IgG4
Structure: Fab only
3.1 Heavy chain
structure length (residues): 235
mutations: No
CDR (residue numbering): 31, 32, 55, 57, 59, 99, 104,-108, 152, 154,
3.2 Light chain
structure length (residues): 213
mutations: No
CDR (residue numbering): 32, 92-94
RCSB PDB - 5GGT: PD-L1 in complex with BMS-936559 Fab
1. Complex: PD-L1 in complex with atezolizumab
Resolution: 3.1 Å
Species: H. sapiens
2. Antigen: Programmed death-ligand 1, PD-L1, cluster of differentiation 274, CD274, B7 homolog 1, B7-H1
structure length (residues): 123
mutations: 1
3. Antibody: atezolizumab
Isotype/subclass: IgG1
Structure: Fab only
3.1 Heavy chain
structure length (residues): 230
mutations: No
disulfide bridges: 22-96, 145-201
CDR (residue numbering): 30, 31, 33, 50, 54, 57-59, 74, 99, 101, 102
3.2 Light chain
structure length (residues): 214
mutations: No
disulfide bridges: 23-88, 134-194
CDR (residue numbering): 30-32, 91-93, 94
RCSB PDB - 5X8L: PD-L1 in complex with atezolizumab
1. Complex: PD-L1 in complex with durvalumab-scFv
Resolution: 2.3 Å
Species: H. sapiens
2. Antigen: Programmed death-ligand 1, PD-L1, cluster of differentiation 274, CD274, B7 homolog 1, B7-H1
structure length (residues): 221
mutations: No
3. Antibody: durvalumab
Isotype/subclass: IgG1k
Structure: Fab only
3.1 Heavy chain
structure length (residues): 121
mutations: No
disulfide bridges: 22-96
CDR (residue numbering): 34, 51, 53, 58, 60, 63, 100, 103, 104-106
3.2 Light chain
structure length (residues): 114
mutations: No
disulfide bridges: 23-89
CDR (residue numbering): 30, 31, 33, 92-95, 97
RCSB PDB - 5XJ4: Complex structure of durvalumab-scFv with PD-L1